AAAAAA
Results:
1-14
|
Results: 14
Authors:
CATO A
QIAN J
HSU A
VOMVOURAS S
PIERGIES AA
LEONARD J
GRANNEMAN R
Citation: A. Cato et al., PHARMACOKINETIC INTERACTION BETWEEN RITONAVIR AND DIDANOSINE WHEN ADMINISTERED CONCURRENTLY TO HIV-INFECTED PATIENTS, Journal of acquired immune deficiency syndromes and human retrovirology, 18(5), 1998, pp. 466-472
Authors:
CATO A
QIAN J
HSU A
LEVY B
LEONARD J
GRANNEMAN R
Citation: A. Cato et al., MULTIDOSE PHARMACOKINETICS OF RITONAVIR AND ZIDOVUDINE IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS, Antimicrobial agents and chemotherapy, 42(7), 1998, pp. 1788-1793
Authors:
CATO A
CAVANAUGH J
SHI H
HSU A
LEONARD J
GRANNEMAN R
Citation: A. Cato et al., THE EFFECT OF MULTIPLE DOSES OF RITONAVIR ON THE PHARMACOKINETICS OF RIFABUTIN, Clinical pharmacology and therapeutics, 63(4), 1998, pp. 414-421
Authors:
GRANNEMAN R
WOZNIAK P
TRANJOHNSON T
SILBER C
MACK R
Citation: R. Granneman et al., POPULATION PHARMACOKINETICS OF SERTINDOLE DURING LONG-TERM TREATMENT OF PATIENTS WITH SCHIZOPHRENIA, Schizophrenia research, 24(1-2), 1997, pp. 202-202
Authors:
SAMARA E
GRANNEMAN R
Citation: E. Samara et R. Granneman, ROLE OF POPULATION PHARMACOKINETICS IN DRUG DEVELOPMENT - A PHARMACEUTICAL-INDUSTRY PERSPECTIVE, Clinical pharmacokinetics, 32(4), 1997, pp. 294-312
Authors:
CATO A
CAO GL
HSU A
CAVANAUGH J
LEONARD J
GRANNEMAN R
Citation: A. Cato et al., EVALUATION OF THE EFFECT OF FLUCONAZOLE ON THE PHARMACOKINETICS OF RITONAVIR, Drug metabolism and disposition, 25(9), 1997, pp. 1104-1106
Authors:
CATO A
QIAN J
CAROTHERS L
CARLSON G
LOCKE C
HSU A
GRANNEMAN R
LEONARD J
Citation: A. Cato et al., EVALUATION OF THE PHARMACOKINETIC INTERACTION BETWEEN RITONAVIR AND DIDANOSINE, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 59-59
Authors:
GRANNEMAN R
ACHARI R
HOSMANE B
Citation: R. Granneman et al., PHARMACOKINETICS AND PHARMACODYNAMICS (PK PD) OF TERAZOSIN IN HYPERTENSIVE PATIENTS/, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 60-60
Authors:
SAMARA E
GRANNEMAN R
LOCKE C
DEAN R
KILLIAN T
Citation: E. Samara et al., PK AND PD OF SERATRODAST IN PATIENTS WITH MODERATE ASTHMA, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 81-81
Authors:
SAMARA E
GRANNEMAN R
Citation: E. Samara et R. Granneman, PK-PD OF SERTINDOLE IN SCHIZOPHRENIC-PATIENTS, Clinical pharmacology and therapeutics, 59(2), 1996, p.
Authors:
NORBECK D
HSU A
GRANNEMAN R
DENISSEN J
KEMPF D
MOLLA A
LEONARD J
Citation: D. Norbeck et al., VIROLOGICAL AND IMMUNOLOGICAL RESPONSE TO RITONAVIR (ABT-538), AN INHIBITOR OF HIV PROTEASE, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 70-70
Authors:
REEDIJK M
BOUCHER CAB
VANBOMMEL T
HO DD
TZENG TB
SERENI D
VEYSSIER P
JURRIAANS S
GRANNEMAN R
HSU A
LEONARD JM
DANNER SA
Citation: M. Reedijk et al., SAFETY, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF A77003, A C-2 SYMMETRY-BASED HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE INHIBITOR, Antimicrobial agents and chemotherapy, 39(7), 1995, pp. 1559-1564
Authors:
SAMARA E
GRANNEMAN R
SAULIS R
WITT G
Citation: E. Samara et al., PHARMACOKINETIC-PHARMACODYNAMIC INTERACTION BETWEEN VALPROATE AND LORAZEPAM, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 153-153
Authors:
SAMARA E
GRANNEMAN R
DUBE L
Citation: E. Samara et al., MICHAELIS-MENTEN KINETICS DETERMINE METABOLIC INTERACTION BETWEEN ZILEUTON AND PHENYTOIN - A POPULATION APPROACH, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 140-140
Risultati:
1-14
|